Safety and humoral response rate of inactivated and mRNA vaccines against SARS-CoV-2 in patients with Multiple Sclerosis
Authors:
- 13 February 2022
- journal article
- research article
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 59, 103690
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Association of Disease-Modifying Treatment and Anti-CD20 Infusion Timing With Humoral Response to 2 SARS-CoV-2 Vaccines in Patients With Multiple SclerosisJAMA Neurology, 2021
- Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapyNature Medicine, 2021
- Dynamic IgG seropositivity after rollout of CoronaVac and BNT162b2 COVID-19 vaccines in Chile: a sentinel surveillance studyThe Lancet Infectious Diseases, 2021
- Characterization of humoral response to COVID mRNA vaccines in multiple sclerosis patients on disease modifying therapiesVaccine, 2021
- Effectiveness of an Inactivated SARS-CoV-2 Vaccine in ChileNew England Journal of Medicine, 2021
- Experience with the COVID-19 AstraZeneca vaccination in people with multiple sclerosisMultiple Sclerosis and Related Disorders, 2021
- Safety and efficacy of COVID-19 vaccines in multiple sclerosis patientsJournal of Neuroimmunology, 2021
- COVID-19 vaccination in patients with multiple sclerosis: What we have learnt by February 2021Multiple Sclerosis Journal, 2021
- Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapiesTherapeutic Advances in Neurological Disorders, 2021
- A Review of the Progress and Challenges of Developing a Vaccine for COVID-19Frontiers in Immunology, 2020